Hybridan

Our USP is that we are profitable from our corporate retained clients. We do not need to be constantly fundraising for companies, IPO or otherwise, even when it might not be the optimal time to do so which can lead to a “float and forget” mentality, completely ignoring aftermarket support for clients.

Hybridan solves this problem – spending our time with corporates on “non-deal activity.”

  • Consistently putting you in front of investors when you don’t need money in a bid to support aftermarket activity.
  • Regular research to ensure your news flow underpins our investment thesis to a targeted pool of institutional investors.
  • Adopting an agnostic approach to our corporate finance advice to ensure capital is raised in a manner that suits your business – private, public, debt or equity.

Our passion is raising growth capital for exciting, fast growth companies that want to take their business to the next level. We raise capital for companies both listed and unlisted in the most efficient manner possible and pride ourselves as being one of the few consistently profitable broking firms in the City. This has been achieved through a highly disciplined approach when seeking to create both corporate and institutional relationships.

We communicate the investment cases of our clients to the market through equity research and frequent non-deal investor road shows. We provide market-driven corporate finance advice to our clients to help deliver shareholder value.

We focus on finding new investors who can buy shares in the market and not just in placings.

Hybridan Team
  • Hybridan Team

Small Cap Feast

Abingdon Healthcare 7.75p £15.01m (ABDX.L) There are two announcements from this developer, manufacturer and distributor of high quality, rapid diagnostic tests. A contract worth $2m with US based, Find Out From Home LLC, for performance evaluation, regulatory services and clinical testing of four STDs (sexually transmitted disease) tests. It begins this month with an initial purchase order for $350,000. It will enable commercialisation of four lateral flow self-tests for HIV, hepatitis B, hepa...

Hybridan Team
  • Hybridan Team

Hybridan Small Cap Feast

Adsure Services 20.50p £2.17m (AQSE:ADS) The specialist and diversified business assurance provider reports Interims to September. It operates across the Housing, Healthcare, Government, Education, Charities offering a wide range of services. There are two operational divisions, Risk & Assurance and the long-established Risk & Advisory. The Interims show a 19% increase in Revenue to £5.1m, its EBITDA jumped to £0.55m against £0.16m, with PBT of £0.33m from a £0.3m loss. This is evidence of th...

Jon Levinson
  • Jon Levinson

Friday Takeway

BBSN.L Big opportunities knock RUA.L Abiss a very going concern

Jon Levinson
  • Jon Levinson

Zentra Group Plc

Firmer Foundations A new journey is under way for 2025 after being transferred onto the Access Segment of the AQSE Growth Market. This listing seems appropriate for the financial stage and its size, while maintaining credibility with counterparties as it sets out to deliver on its new plans. Business was transformative in 2024, with a significant restructuring including the discontinuation of its co-living and in-house construction services. The loss before tax to Y/E June 2024 increased to £3....

Hybridan Small Cap Feast

* A corporate client of Hybridan LLP ** Potential means Intention to Float (ITF) has been announced, or it is a rumour ***Arranged by type of listing and date of announcement ****Alphabetically arranged Share prices and market capitalisations taken from the current price on the day of publication Dish of the day Admissions: Zentra Group 4p £1.55m (Aquis: ZNT)* has delisted from the Equity Transition Segment of the Main Market on and admitted to the Access Segment of the AQSE Growth Mark...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch